Tadalafil – Long-Acting PDE5 Inhibitor for ED and BPH
Tadalafil is a reversible, selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE-5). The drug was developed for the pathogenic therapy of erectile dysfunction (ED), symptoms of benign prostatic hyperplasia (BPH), and pulmonary arterial hypertension (PAH). Its mechanism of action is based on the blockade of the PDE-5 enzyme, which prevents the hydrolysis of cGMP in vascular smooth muscle cells. This leads to the accumulation of cGMP, prolonged relaxation of smooth muscles, dilation of arterioles, and increased blood flow to the corpora cavernosa of the penis during sexual stimulation, as well as a decrease in pressure within the pulmonary vascular bed.
A unique pharmacokinetic feature of tadalafil that distinguishes it from other PDE-5 inhibitors (such as sildenafil or vardenafil) is its long half-life, which is approximately 17.5 hours. This provides an unprecedented duration of therapeutic effect — up to 36 hours after a single dose, earning the drug the unofficial nickname "the weekend pill." This prolonged window of efficacy allows patients to engage in sexual activity spontaneously without the need to plan ahead, thereby reducing psychological stress. The drug effectively improves pelvic organ perfusion, helping to ameliorate lower urinary tract symptoms associated with BPH. Tadalafil is rapidly absorbed after oral administration, and its bioavailability and onset of action are not affected by high-fat meals or alcohol consumption.
The drug is administered orally. To achieve a therapeutic effect for erectile dysfunction, the presence of natural sexual stimulation is an absolute prerequisite.
Indications
Tadalafil is indicated for the treatment of adult patients with the following clinical conditions:
- Erectile Dysfunction: therapy for erectile disturbances characterized by the inability to attain or maintain a penile erection sufficient for satisfactory sexual performance.
- Benign Prostatic Hyperplasia (BPH): management of lower urinary tract symptoms in patients with prostate enlargement (either associated with ED or as monotherapy).
- Pulmonary Hypertension (PAH): pathogenic treatment of WHO Functional Class I–IV pulmonary arterial hypertension to improve exercise capacity.
Dosage and administration
The dosing regimen of tadalafil depends on the indication, severity of the disease, and the chosen management strategy (on-demand or daily use).
- For "on-demand" ED therapy: the recommended starting dose is 20 mg, taken at least 30 to 40 minutes prior to anticipated sexual activity.
- For once-daily use (ED and/or BPH): the regular dose is 5 mg taken orally once daily at approximately the same time, regardless of the timing of sexual activity.
- For Pulmonary Arterial Hypertension (PAH): the standard daily dose is 40 mg (two 20 mg tablets) taken once daily.
- Administration Method: tablets are swallowed whole with water, with or without food. Splitting or chewing the tablets is not recommended.
- Dose Adjustment: in patients with moderate renal or hepatic impairment, the maximum dose for on-demand use should not exceed 10 mg.